Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) reached a new 52-week low on Friday . The stock traded as low as $28.78 and last traded at $28.69, with a volume of 281860 shares trading hands. The stock had previously closed at $34.18.
Analyst Ratings Changes
Several research firms have recently issued reports on VERA. Wedbush upped their price target on Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a research note on Friday, November 8th. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price for the company. Wolfe Research assumed coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price target on the stock. Guggenheim boosted their price objective on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a research note on Monday, October 28th. Finally, JPMorgan Chase & Co. raised their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $65.44.
Read Our Latest Research Report on Vera Therapeutics
Vera Therapeutics Stock Up 6.3 %
The firm's 50-day simple moving average is $38.16 and its 200-day simple moving average is $40.79. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -11.18 and a beta of 1.11.
Insider Buying and Selling
In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the transaction, the chief executive officer now directly owns 143,603 shares of the company's stock, valued at approximately $5,993,989.22. This trade represents a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 52,500 shares of company stock valued at $2,305,625 over the last three months. 21.70% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Vera Therapeutics
Several large investors have recently made changes to their positions in the company. Huntington National Bank bought a new stake in Vera Therapeutics during the fourth quarter worth about $26,000. AlphaQuest LLC bought a new stake in Vera Therapeutics during the 4th quarter worth approximately $34,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Vera Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company's stock valued at $86,000 after purchasing an additional 350 shares in the last quarter. KBC Group NV increased its holdings in Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after purchasing an additional 1,387 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its position in shares of Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after purchasing an additional 639 shares in the last quarter. Institutional investors own 99.21% of the company's stock.
About Vera Therapeutics
(
Get Free Report)
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Featured Stories
Before you consider Vera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.
While Vera Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
